BioGaia AB (publ)

BIOG-B · Nasdaq Stockholm · Healthcare

114.00SEK +0.3%last day

Price as of 2 October 2026

The price over the past year, with dividends: +9.7%

Performance

1 month

+2.2%

1 year

+9.7%

3 years, per year

+10.3%

5 years, per year

+9.8%

Largest fall, 3 years

−29.3%

Below the peak now

−15.5%

Volatility, 1 year

28.3%

Return with dividends reinvested.

Key figures

P/E

32.1

P/B

10.1

Dividend yield

3.5%

Return on equity

+31.5%

Net margin

+22.0%

Market value

1.1 bn USD

Quality, value and trend

Where BioGaia stands against every Nordic stock today. 100 is best.

Quality100

Profitability and a sound balance sheet over time. Better than 100% of Nordic stocks.

Value12

The price measured against earnings, assets and cash flow. Better than 12% of Nordic stocks.

Trend50

The price development over the past year. Better than 50% of Nordic stocks.

Combined54

Quality, value and trend together. Better than 54% of Nordic stocks.

About BioGaia

BioGaia AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 250 employees.

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis